• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.

作者信息

Fakharian Atefeh, Barati Saghar, Mohamadi Monir, Dastan Farzaneh

机构信息

Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

J Cardiothorac Vasc Anesth. 2022 Apr;36(4):1115-1117. doi: 10.1053/j.jvca.2020.12.023. Epub 2021 Jan 8.

DOI:10.1053/j.jvca.2020.12.023
PMID:33423911
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833423/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/673b/7833423/9c78e40bf4f7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/673b/7833423/9c78e40bf4f7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/673b/7833423/9c78e40bf4f7/gr1_lrg.jpg

相似文献

1
Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.阿达木单抗成功治疗冠状动脉搭桥术后COVID-19患者
J Cardiothorac Vasc Anesth. 2022 Apr;36(4):1115-1117. doi: 10.1053/j.jvca.2020.12.023. Epub 2021 Jan 8.
2
COVID-19 - Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?新冠病毒-内皮轴与冠状动脉搭桥术通畅性：治疗干预靶点？
Braz J Cardiovasc Surg. 2020 Oct 1;35(5):757-763. doi: 10.21470/1678-9741-2020-0303.
3
Successful coronary artery bypass operation in a SARS-COV-2 infected patient with acute coronary syndrome.一名感染新型冠状病毒肺炎的急性冠状动脉综合征患者成功接受冠状动脉搭桥手术。
J Card Surg. 2020 Sep;35(9):2361-2363. doi: 10.1111/jocs.14784. Epub 2020 Jul 11.
4
A 48-Year-Old Man at Low Risk for SARS-CoV-2 Infection Who Underwent Planned Elective Triple-Vessel Coronary Artery Bypass Graft Surgery at a National Heart Center in Indonesia Followed by a Fatal Case of COVID-19.一位 48 岁的男子，感染 SARS-CoV-2 的风险较低，在印度尼西亚的一家国家心脏中心接受了计划中的三血管冠状动脉旁路移植手术，随后 COVID-19 死亡。
Am J Case Rep. 2021 Jan 25;22:e928900. doi: 10.12659/AJCR.928900.
5
Impact of the COVID-19 pandemic on coronary artery bypass graft surgery in Brazil: A nationwide perspective.COVID-19 大流行对巴西冠状动脉旁路移植手术的影响：全国视角。
J Card Surg. 2021 Sep;36(9):3289-3293. doi: 10.1111/jocs.15765. Epub 2021 Jun 20.
6
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer.回复：“在阿达木单抗治疗下的强直性脊柱炎患者接种 SARS-CoV-2 疫苗后 7 天发生带状疱疹”，Josef Finsterer 著。
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.
7
Coronary artery bypass grafting surgery versus percutaneous coronary intervention: What is the clinical decision framework amid COVID-19 era?冠状动脉旁路移植术与经皮冠状动脉介入治疗：在新冠疫情时代临床决策框架是什么？
J Card Surg. 2020 Oct;35(10):2464-2466. doi: 10.1111/jocs.14833. Epub 2020 Jul 11.
8
COVID-19 Patients With Previous Coronary Artery By-Pass Graft Have a Higher Mortality Risk.曾接受冠状动脉搭桥手术的COVID-19患者有更高的死亡风险。
Am J Cardiol. 2021 Nov 15;159:146-148. doi: 10.1016/j.amjcard.2021.08.010. Epub 2021 Aug 16.
9
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.一名患有银屑病和银屑病关节炎的患者在使用阿达木单抗治疗期间COVID-19感染的非复杂病程。
Dermatol Ther. 2020 Jul;33(4):e13708. doi: 10.1111/dth.13708. Epub 2020 Jun 26.
10
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab.患者患有强直性脊柱炎，正在接受阿达木单抗治疗，接种 SARS-CoV-2 疫苗后 7 天发生带状疱疹。
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.

引用本文的文献

1
A Review of Potential Therapeutic Strategies for COVID-19.《COVID-19 的潜在治疗策略综述》
Viruses. 2022 Oct 25;14(11):2346. doi: 10.3390/v14112346.
2
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.国家结核病和肺部疾病研究所（NRITLD）新冠病毒病患者治疗方案
Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec.
3
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.

本文引用的文献

1
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
2
Treatment Approach to Coronavirus Disease (COVID-19) Seen Early After Open Heart Surgery. Case Report.心脏直视手术后早期出现的冠状病毒病（COVID-19）的治疗方法。病例报告。
SN Compr Clin Med. 2020;2(8):1208-1212. doi: 10.1007/s42399-020-00377-y. Epub 2020 Jul 2.
3
Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19.
新型冠状病毒肺炎被动免疫治疗的最新进展：基于证据的方法和临床试验。
Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.
4
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.窥探潘多拉魔盒：新冠病毒与神经退行性变
Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.
5
Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial.评估阿达木单抗治疗 COVID-19 重症病例的效果：一项随机对照试验。
Int Immunopharmacol. 2021 Oct;99:107961. doi: 10.1016/j.intimp.2021.107961. Epub 2021 Jul 7.
6
Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives.抗 SARS-CoV-2 和抗细胞因子风暴中和抗体疗法治疗 COVID-19：最新进展、挑战与展望。
Int Immunopharmacol. 2021 Oct;99:108036. doi: 10.1016/j.intimp.2021.108036. Epub 2021 Aug 3.
7
The role of CD4FoxP3 regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment.CD4FoxP3调节性T细胞在新型冠状病毒肺炎免疫发病机制中的作用：对治疗的启示
Int J Biol Sci. 2021 Apr 10;17(6):1507-1520. doi: 10.7150/ijbs.59534. eCollection 2021.
8
Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology.2019年新型冠状病毒病（COVID-19）与细胞因子风暴：基于炎症病理生理学的更有效治疗方法
J Clin Med. 2021 Feb 17;10(4):801. doi: 10.3390/jcm10040801.
血浆置换、抗ACE2和抗FcγRII单克隆抗体：COVID-19重症病例的一种可能治疗方法。
Drug Des Devel Ther. 2020 Jul 6;14:2607-2611. doi: 10.2147/DDDT.S262491. eCollection 2020.
4
Coronavirus Disease 2019: Associated Multiple Organ Damage.2019冠状病毒病：相关的多器官损伤
Open Forum Infect Dis. 2020 Jun 21;7(7):ofaa249. doi: 10.1093/ofid/ofaa249. eCollection 2020 Jul.
5
COVID-19 in patients with rheumatological diseases treated with anti-TNF.接受抗TNF治疗的风湿性疾病患者中的COVID-19
Ann Rheum Dis. 2021 May;80(5):e62. doi: 10.1136/annrheumdis-2020-218171. Epub 2020 Jun 16.
6
Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.金属蛋白酶抑制在新型冠状病毒肺炎所致严重肺损伤治疗中的应用
Med Drug Discov. 2020 Sep;7:100052. doi: 10.1016/j.medidd.2020.100052. Epub 2020 Jun 5.
7
A current review of COVID-19 for the cardiovascular specialist.心血管专家必读：关于 COVID-19 的最新综述。
Am Heart J. 2020 Aug;226:29-44. doi: 10.1016/j.ahj.2020.04.025. Epub 2020 May 3.
8
Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19.炎症性肠病中的抗TNF-α药物与COVID-19病程
Inflamm Bowel Dis. 2020 Jun 18;26(7):e73. doi: 10.1093/ibd/izaa114.
9
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.4例接受生物制剂治疗的银屑病患者的新型冠状病毒肺炎感染演变情况
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
10
COVID-19 infection in Crohn's disease under treatment with adalimumab.在用阿达木单抗治疗的克罗恩病患者中发生的新型冠状病毒肺炎感染
Gut. 2020 Jul;69(7):1364-1365. doi: 10.1136/gutjnl-2020-321240. Epub 2020 Apr 20.